
Recombinant Human MMP16 protein (His Tag)

Catalog Number: PDEH101036

Note: Centrifuge before opening to ensure complete recovery of vial contents.

| Description | |
|----------------|---|
| Species | Human |
| Source | E.coli-derived Human MMP16 protein Ala151-Lys450, with an N-terminal His & C- |
| | terminal His |
| Calculated MW | 32.9 kDa |
| Observed MW | 35 kDa |
| Accession | P51512 |
| Bio-activity | Not validated for activity |
| Properties | |
| Purity | > 95% as determined by reducing SDS-PAGE. |
| Endotoxin | < 10 EU/mg of the protein as determined by the LAL method |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -8 |
| | °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of |
| | reconstituted samples are stable at $< -20^{\circ}$ C for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from a 0.2 μ m filtered solution in PBS with 5% Trehalose and 5% |
| | Mannitol. |
| Reconstitution | It is recommended that sterile water be added to the vial to prepare a stock solution o |
| | 0.5 mg/mL. Concentration is measured by UV-Vis. |

Data



> 95 % as determined by reducing SDS-PAGE.

Background

Elabscience®

Matrix metalloproteinases (MMPs) are a family of zinc and calcium dependent endopeptidases with the combined ability to degrade all the components of the extracellular matrix (ECM). MMP-16 (MT3-MMP) is found in brain, lung, placenta, smooth muscle cells, and malignant tumor tissues including oral melanoma and renal carcinoma . MMP-16 has been shown to activate proMMP-2 and degrade various ECM components including native collagens. MMP-16 has been proposed to possess the potential to directly enhance the growth and invasiveness of cells in vivo, two critical processes for development and carcinogenesis . Structurally, MMP-16 consists of the following domains: a pro domain containing the furin cleavage site, a catalytic domain containing the zinc-binding site, a hinge region, a hemopexin-like domain, a transmembrane domain, and a cytoplamasic tail . The structure of the catalytic domain in complex with a hydroxamate inhibitor has been solved . The rhMMP-16PC consists of the pro and catalytic domains, which can be activated by treatment with furin.